IPP Bureau
Lupin to acquire supplements portfolio of Anglo-French Drugs & Industries for Rs 325 crore
By IPP Bureau - January 18, 2022
The acquisition would enable addition of established brands with high recall amongst healthcare professionals, especially in the vitamins, minerals and supplements category
Philips integrates cloud-based AI and 3D mapping into Zenition
By IPP Bureau - January 18, 2022
New capabilities on Philips Image Guided therapy mobile C-arm system – Zenition – and collaboration with Cydar offer the latest advances in endovascular treatment
.jpg "TPVI offers a ray of hope for children with Pulmonic Valve disease")
TPVI offers a ray of hope for children with Pulmonic Valve disease
By IPP Bureau - January 18, 2022
Extending nonsurgical treatment options for Failing Pulmonic Valve in patients with congenital heart disease using Transcatheter Pulmonary Valve
Solvay awards €300k science prize to Prof Katalin Kariko for research in mRNA technology
By IPP Bureau - January 18, 2022
Prof Karikó's research was most notably used by Pfizer/BioNTech and Moderna to build COVID-19 mRNA vaccines
DCGI approves Phase 3 clinical trial of Stempeucel to treat Covid-19 patients
By IPP Bureau - January 18, 2022
The drug is aimed at treating Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS)
Cosette Pharma acquires rights to Daiichi Sankyo’s eight branded products
By IPP Bureau - January 18, 2022
As part of Daiichi Sankyo’s 2030 vision, it plans to strengthen its oncology portfolio
BiologyWorks k(now) handheld molecular device 99.1 % accurate to RT-PCR test
By IPP Bureau - January 18, 2022
Results from the BiologyWorks k(now) molecular test were 99.1% in overall percent agreement with the results of the RT-PCR lab tests
Anurag Yadav is the new Chief Executive Officer of IHH Healthcare India
By IPP Bureau - January 17, 2022
Prior to IHH, Anurag held senior leadership roles in Fortis Healthcare and Manipal Health Enterprises.
Glenmark Pharmaceuticals receives ANDA tentative approval for Regadenoson injection
By IPP Bureau - January 17, 2022
The company has 47 ANDA's pending approval with the U.S.FDA
Dr Charles Woler is the new Chairman of Sygnature Discovery
By IPP Bureau - January 17, 2022
Dr Woler joins Sygnature Discovery after the company received significant investment from Five Arrows Principal Investments, the European corporate private equity arm of Rothschild & Co, in 2021
Green Valley receives US FDA approval for Phase II clinical trial for Parkinson’s disease
By IPP Bureau - January 17, 2022
The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period
ICRA expects hospitals to report robust revenue and margin expansion in FY22
By IPP Bureau - January 17, 2022
Occupancy is expected to be in the range of 60-62% while Average Revenue Per Occupied Bed (ARPOB) is expected to expand by least 6% in FY2022
SeQuent Scientific appoints Rajaram Narayanan as MD & CEO
By IPP Bureau - January 17, 2022
Narayanan to lead SeQuent through next phase of consolidation and growth
Strides receives USFDA approval for influenza medicine
By IPP Bureau - January 17, 2022
The company has 271 cumulative ANDA filings with USFDA of which 243 ANDAs have been approved and 28 are pending approval
WHO recommends two new drugs for COVID-19
By IPP Bureau - January 14, 2022
Their strong recommendation is based on moderate certainty evidence that it improves survival and reduces the need for ventilation
